1
|
Rachamalla HK, Bhattacharya S, Ahmad A, Sridharan K, Madamsetty VS, Mondal SK, Wang E, Dutta SK, Jan BL, Jinka S, Chandra Sekhar Jaggarapu MM, Yakati V, Mukhopadhyay D, Alkharfy KM, Banerjee R. Enriched pharmacokinetic behavior and antitumor efficacy of thymoquinone by liposomal delivery. Nanomedicine (Lond) 2021; 16:641-656. [PMID: 33769068 DOI: 10.2217/nnm-2020-0470] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022] Open
Abstract
Background: Thymoquinone (TQ) has potential anti-inflammatory, immunomodulatory and anticancer effects but its clinical use is limited by its low solubility, poor bioavailability and rapid clearance. Aim: To enhance systemic bioavailability and tumor-specific toxicity of TQ. Materials & methods: Cationic liposomal formulation of TQ (D1T) was prepared via ethanol injection method and their physicochemical properties, anticancer effects in orthotopic xenograft pancreatic tumor model and pharmacokinetic behavior of D1T relative to TQ were evaluated. Results: D1T showed prominent inhibition of pancreatic tumor progression, significantly greater in vivo absorption, approximately 1.5-fold higher plasma concentration, higher bioavailability, reduced volume of distribution and improved clearance relative to TQ. Conclusion: Encapsulation of TQ in cationic liposomal formulation enhanced its bioavailability and anticancer efficacy against xenograft pancreatic tumor.
Collapse
Affiliation(s)
- Hari Krishnareddy Rachamalla
- Applied Biology Division, CSIR-Indian Institute of Chemical Technology, Uppal Road, Hyderabad, Telangana 500007, India
| | - Santanu Bhattacharya
- Department of Biochemistry & Molecular Biology, Mayo Clinic College of Medicine & Science, Jacksonville, FL, USA.,Department of Physiology & Biomedical Engineering, Mayo Clinic College of Medicine & Science, Jacksonville, FL, USA
| | - Ajaz Ahmad
- Department of Clinical Pharmacy, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia
| | - Kathyayani Sridharan
- Applied Biology Division, CSIR-Indian Institute of Chemical Technology, Uppal Road, Hyderabad, Telangana 500007, India
| | - Vijay Sagar Madamsetty
- Department of Biochemistry & Molecular Biology, Mayo Clinic College of Medicine & Science, Jacksonville, FL, USA
| | - Sujan Kumar Mondal
- Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA.,UPMC Hilman Cancer Center, Pittsburgh, PA 15232, USA
| | - Enfeng Wang
- Department of Biochemistry & Molecular Biology, Mayo Clinic College of Medicine & Science, Jacksonville, FL, USA
| | - Shamit K Dutta
- Department of Biochemistry & Molecular Biology, Mayo Clinic College of Medicine & Science, Jacksonville, FL, USA
| | - Basit L Jan
- Department of Clinical Pharmacy, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia
| | - Sudhakar Jinka
- Applied Biology Division, CSIR-Indian Institute of Chemical Technology, Uppal Road, Hyderabad, Telangana 500007, India
| | | | - Venu Yakati
- Applied Biology Division, CSIR-Indian Institute of Chemical Technology, Uppal Road, Hyderabad, Telangana 500007, India
| | - Debabrata Mukhopadhyay
- Department of Biochemistry & Molecular Biology, Mayo Clinic College of Medicine & Science, Jacksonville, FL, USA.,Department of Physiology & Biomedical Engineering, Mayo Clinic College of Medicine & Science, Jacksonville, FL, USA
| | - Khalid M Alkharfy
- Department of Clinical Pharmacy, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia
| | - Rajkumar Banerjee
- Applied Biology Division, CSIR-Indian Institute of Chemical Technology, Uppal Road, Hyderabad, Telangana 500007, India
| |
Collapse
|
2
|
Jinka S, Rachamalla HK, Bhattacharyya T, Sridharan K, Sekhar Jaggarapu MMC, Yakati V, Banerjee R. Glucocorticoid receptor-targeted liposomal delivery system for delivering small molecule ESC8 and anti-miR-Hsp90 gene construct to combat colon cancer. Biomed Mater 2021; 16:024105. [PMID: 33434900 DOI: 10.1088/1748-605x/abdb08] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Abstract
High mortality rate in colon cancer patients is often attributed to late diagnosis. To overcome the conventional chemotherapy associated challenges, chemotherapeutic drugs (single or combination) or genetic drugs are often delivered using ligand-modified delivery systems that selectively target over expressed receptors or particular receptors that act abnormally in cancer cells. In the current investigation, first we assessed anti-colon cancer effect of a cationic estrogenic molecule, ESC8 which was earlier shown to act against estrogen receptor (ER) ± breast cancer cells. We found that against both colon and breast cancer cells the anticancer activity is intervened by AMPK-mTOR pathway and at the same time it acts as anti-angiogenic agent. It also showed enhancement of mesenchymal-to-epithelial (MET) transition as well as reduction of cyclin D in both cells. Earlier we demonstrated the use of glucocorticoid receptor (GR) targeted cationic liposomal delivery system carrying anti-Hsp90 plasmid and ESC8 to act as potent anti-skin cancer therapeutics. As ESC8 demonstrated anti-colon cancer effect in vitro, in here, we used the same GR-targeted liposomal formulation but carrying a more fusogenic cationic lipid D1 and used against colon tumor orthotopic model in mice. We show that GR targeted formulation (D1XE-Hsp90) exhibited efficient cellular uptake, transfection and selective cytotoxicity in colon cancer cells, tumor-targeted bio-distribution and enhanced survivability, reduced tumor size in orthotopic colon tumor-bearing mice. The tumor sections exhibited reduced tumor proliferation as well as neo-vascularization, thus supporting the holistic antitumor effect of the D1XE-Hsp90 formulation. Over all our results establish the GR-targeted D1XE-Hsp90 formulation as potent anti-colon cancer therapeutics.
Collapse
Affiliation(s)
- Sudhakar Jinka
- Applied Biology Division, CSIR-Indian Institute of Chemical Technology, Uppal Road, Hyderabad, Telangana 500007, India. Academy of Scientific & Innovative Research (AcSIR), CSIR-HRDC Campus, Ghaziabad, Uttar Pradesh 201002, India
| | | | | | | | | | | | | |
Collapse
|
3
|
Saha S, Yakati V, Shankar G, Jaggarapu MMCS, Moku G, Madhusudana K, Banerjee R, Ramkrishna S, Srinivas R, Chaudhuri A. Amphetamine decorated cationic lipid nanoparticles cross the blood-brain barrier: therapeutic promise for combating glioblastoma. J Mater Chem B 2020; 8:4318-4330. [PMID: 32330214 DOI: 10.1039/c9tb02700a] [Citation(s) in RCA: 30] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/17/2023]
Abstract
Combating brain tumors (glioblastoma multiforme or GBM) is a formidable challenge because of the existence of blood-brain barrier (BBB), a tight cellular junction that separates the central nervous system (CNS) and systemic circulation. Such a selectively permeable barrier prevents the entry of therapeutic molecules from blood circulation to brain parenchyma. Towards enhancing the efficacy of brain tumor-selective drug delivery without perturbing the BBB integrity, nanometric drug carriers are increasingly becoming an efficient therapeutic modality in preclinical studies. Psychostimulant drugs such as amphetamine and methylated amphetamine (METH) are known to penetrate the BBB. Still, little effort has been made to exploit them in nano-drug delivery, largely due to their toxicities. Herein, for the first time, we design, synthesize, and formulate three different β-amphetaminylated cationic lipid nanoparticles. We show that the β-amphetaminylated cationic lipid nanoparticles are nontoxic and can cross the BBB presumably through active transcytosis. The BBB penetrating ability also depends on the hydrophilic-hydrophobic balance of the lipids, with hexadecyl lipid (16-BACL) nanoparticle showing maximum accumulation in the brain. The lipid nanoparticle of 16-BACL can simultaneously encapsulate paclitaxel and PDL1-siRNA. The dual drug-loaded lipid nanoparticles showed apoptosis driven cellular cytotoxicity against GL261 cells and improved the overall survivability of orthotopic glioblastoma bearing mice compared to their non-targeting counterpart. The present work describes a new class of BBB-crossing lipid nanoparticles and delineates their therapeutic promise against glioblastoma.
Collapse
Affiliation(s)
- Soumen Saha
- Applied Biology Division, CSIR - Indian Institute of Chemical Technology (CSIR-IICT), Uppal Road, Tarnaka, Hyderabad 500 007, Telangana State, India.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
4
|
Rachamalla HK, Mondal SK, Deshpande SS, Sridharan K, Javaji K, Jaggarapu MMCS, Jinka S, Bollu V, Misra S, Banerjee R. Efficient anti-tumor nano-lipoplexes with unsaturated or saturated lipid induce differential genotoxic effects in mice. Nanotoxicology 2019; 13:1161-1175. [PMID: 31294672 DOI: 10.1080/17435390.2019.1643049] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
Abstract
Cationic lipids are well-known excipients for nanometric liposomal gene delivery systems. However, because of the suspected, collateral toxicity in normal cells, the use of cationic lipids for the treatment of human tumor is largely limited. Recently, we developed a glucocorticoid receptor (GR)-targeted liposomal, anticancer delivery system (DXE nano-lipoplex), which carried cationic lipid of saturated twin aliphatic chains. It exhibited efficient anti-tumor effect in aggressive and drug-resistant tumor models. Toward exploring lipoplex's human clinical use, we incorporated another nano-lipoplex (D1XE) group that carried cationic lipid with one of its aliphatic chain carrying unsaturation and compared in vivo genotoxicological profiling-based safety assessment and the respective anti-tumor efficacy of the lipoplexes. Thus, both the lipoplexes differ only by the chemical identity of one of their constituent cationic lipid. Unsaturated aliphatic chains in lipid generally impart efficient cell surface fusogenic property in lipid formulations. Herein, we report that nanoplex with unsaturated cationic lipid (D1XE) exhibited better physical appearance with less flocculent behavior than nanoplex with saturated lipid (DXE). Upon multiple injections, D1XE nanoplex imparted better tumor regression but most importantly, exhibited much lower overall toxicity (e.g. genotoxicity, weight loss, etc.) than DXE nanoplex. With a higher antitumor effect but a lower genotoxic effect, D1XE is proved to be a better nanoplex than DXE for the potential clinical trial. Thus, this study clearly delineates the importance of incorporating a constituent lipid that carries a single unsaturated aliphatic chain toward developing efficient anti-tumor nano-lipoplexes with reduced genotoxicity.
Collapse
Affiliation(s)
- Hari Krishnareddy Rachamalla
- Applied Biology Division, CSIR-Indian Institute of Chemical Technology , Hyderabad , India.,Academy of Scientific & Innovative Research (AcSIR), CSIR-HRDC Campus , Ghaziabad , India
| | - Sujan Kumar Mondal
- Applied Biology Division, CSIR-Indian Institute of Chemical Technology , Hyderabad , India.,Academy of Scientific & Innovative Research (AcSIR), CSIR-HRDC Campus , Ghaziabad , India
| | - Shruti S Deshpande
- Applied Biology Division, CSIR-Indian Institute of Chemical Technology , Hyderabad , India.,Academy of Scientific & Innovative Research (AcSIR), CSIR-HRDC Campus , Ghaziabad , India
| | - Kathyayani Sridharan
- Applied Biology Division, CSIR-Indian Institute of Chemical Technology , Hyderabad , India.,Academy of Scientific & Innovative Research (AcSIR), CSIR-HRDC Campus , Ghaziabad , India
| | - Kalpana Javaji
- Applied Biology Division, CSIR-Indian Institute of Chemical Technology , Hyderabad , India.,Academy of Scientific & Innovative Research (AcSIR), CSIR-HRDC Campus , Ghaziabad , India
| | - Madan Mohan Chandra Sekhar Jaggarapu
- Applied Biology Division, CSIR-Indian Institute of Chemical Technology , Hyderabad , India.,Academy of Scientific & Innovative Research (AcSIR), CSIR-HRDC Campus , Ghaziabad , India
| | - Sudhakar Jinka
- Applied Biology Division, CSIR-Indian Institute of Chemical Technology , Hyderabad , India.,Academy of Scientific & Innovative Research (AcSIR), CSIR-HRDC Campus , Ghaziabad , India
| | - Vishnusravan Bollu
- Applied Biology Division, CSIR-Indian Institute of Chemical Technology , Hyderabad , India.,Academy of Scientific & Innovative Research (AcSIR), CSIR-HRDC Campus , Ghaziabad , India
| | - Sunil Misra
- Applied Biology Division, CSIR-Indian Institute of Chemical Technology , Hyderabad , India.,Academy of Scientific & Innovative Research (AcSIR), CSIR-HRDC Campus , Ghaziabad , India
| | - Rajkumar Banerjee
- Applied Biology Division, CSIR-Indian Institute of Chemical Technology , Hyderabad , India.,Academy of Scientific & Innovative Research (AcSIR), CSIR-HRDC Campus , Ghaziabad , India
| |
Collapse
|